- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05478577
Clinical Features and Rehabilitation Effect in Patients With Stroke (PCR)
August 3, 2022 updated by: Silvia Salvalaggio, IRCCS San Camillo, Venezia, Italy
Clinical Features and Rehabilitation Effect for Upper Limb Recovery in Patients With Stroke: Retrospective Study
Dosage of rehabilitation therapy is a key factor in promoting motor functional recovery after stroke.
To date, what is not yet known are the clinical features (e.g. the neurological profile, clinical history, motor, language and cognitive abilities), which allow the clinician to predict the recovery potential of a patient before rehabilitation, based on both the initial assessment and the various treatment pathways available in the National Health System.
For these reasons, the study aims to explore clinical features and potential effect of rehabilitation dose that could influence upper limb motor recovery
Study Overview
Detailed Description
Dosage of rehabilitation therapy is a key factor in promoting motor functional recovery after stroke.
Moreover, even though recent evidence has shown that cognitive abilities may support motor recovery, the relationship between cognitive-linguistic and motor skills in stroke patients is still a matter of research.
Regarding the dose of intervention, in trials in which patients underwent 6 hours of rehabilitation per day, functional improvements in the upper limb reached clinically relevant levels, up to a difference of 8-11 points on the Fugl-Meyer Upper Extremity.
To date, evidence of clinical (e.g.
motor, cognitive-linguistic and neurological) and rehabilitation features that may influence upper limb recovery are still missing.
Therefore, this study aims to retrospectively explore whether there is a relationship between clinical features and upper limb recovery after rehabilitation in stroke patients.
Study Type
Observational
Enrollment (Actual)
35
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Venice
-
Venezia, Venice, Italy, 30126
- San Camillo IRCCS Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adults with stroke hospitalised at San Camillo Hospital for a period of neurological rehabilitation
Description
Inclusion Criteria:
- age > 18 years
- first-ever unilateral cortical-subcortical stroke, (ischemic or haemorrhagic)
- completed at least 4 weeks of rehabilitation
- preserved ability or possibility to provide informed consent.
Exclusion Criteria:
- cerebellar or bilateral stroke
- unstable medical conditions;
- diagnosis of other neurological and/or psychiatric diseases in addition to stroke;
- traumatic brain injury;
- not released informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fugl-Meyer Assessment Upper Extremity
Time Frame: change from baseline up to 8 weeks
|
Fugl-Meyer Assessment Upper Extremity is a stroke-specific scale which assesses the upper limb motor functioning in patients with post-stroke hemiplegia.
There are 3 values: 0 (severe impairment), 1 (moderate impairment), 2 (preserved function).
The minimum value is 0 points, which corresponds to upper limb hemiplegia.
The maximum value is 66 points, which corresponds to normal motor performance.
|
change from baseline up to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reaching Performance Scale
Time Frame: Change from baseline up to 8 weeks.
|
Reaching Performance Scale assesses the ability of subjects to reach an object (a cone).
The cone is placed at both 4-cm (close) and 30-cm (far) distance from the subject.
The subject is asked to reach and grab the cone if possible.
The observer evaluates the quality of reaching instead of the grip strength.
The minimum value is 0 points, which corresponds to incapacity of any ability of reaching an object.
The maximum value is 36 points, which corresponds to the preservation of the ability of reaching an object.
|
Change from baseline up to 8 weeks.
|
|
Box & Blocks Test
Time Frame: Change from baseline up to 8 weeks.
|
The patient has to carry as much cubes as possible, one by one, from a container to another one in one minute.
The test is performed with both hands.
|
Change from baseline up to 8 weeks.
|
|
Oxford Cognitive Screen
Time Frame: at baseline
|
Oxford Cognitive Screen is a multidomains screening tool for the assessment of cognitive functions (e.g.
attention, executive functions, linguistic functions, memory).
For each domain, cut-off scores are calculated according to age and education levels.
There is not an overall score, but for each domain pathological performances are identified according to normative data.
|
at baseline
|
|
Modified Ashworth Scale
Time Frame: Change from baseline up to 8 weeks.
|
Spasticity is measured using the Modified Ashworth Scale of biceps muscle (Total score = 20 points).
The therapist evaluates the spasticity of the muscle.
There are 5 values: 0 (no increase in muscle tone), 1 (slight increase in muscle tone), 2 (more marked increase in muscle tone), 3 (considerable increase in muscle tone), 4 (affected part rigid in flexion or extension).
|
Change from baseline up to 8 weeks.
|
|
Functional Independence Measure
Time Frame: Change from baseline up to 8 weeks.
|
Functional Independence Measure scale is an 18-item scale that assesses the degree of independence in carrying out activities of daily living.
There are 7 values: 1 (Total Assistance or not Testable), 2 (Maximal Assistance), 3 (Moderate Assistance), 4 (Minimal Assistance), 5 (Supervision), 6 (Modified Independence), 7 (Complete Independence).
The minimum values is 18 points, which corresponds to the lower level of independence in activities of daily living.
The maximum value is 126 points, which corresponds to the maximum level of independence in activities of daily living.
|
Change from baseline up to 8 weeks.
|
|
Dose of therapy
Time Frame: hospitalisation period (8 weeks)
|
Amount (in hours) of rehabilitation that patients underwent during hospitalisation
|
hospitalisation period (8 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 1, 2021
Primary Completion (ACTUAL)
December 31, 2021
Study Completion (ACTUAL)
December 31, 2021
Study Registration Dates
First Submitted
July 26, 2022
First Submitted That Met QC Criteria
July 26, 2022
First Posted (ACTUAL)
July 28, 2022
Study Record Updates
Last Update Posted (ACTUAL)
August 5, 2022
Last Update Submitted That Met QC Criteria
August 3, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCR 2021.20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
National Assembly ClinicBayero University Kano, NigeriaRecruitingStroke | Stroke Hemorrhagic | Stroke Ischemic | Hemiparesis After StrokeNigeria
-
University of PittsburghRecruitingHemorrhagic Stroke | Embolic Stroke of Undetermined Source | Ischemic Stroke, Cryptogenic | Recurrent Ischemic Stroke | Ischemic Stroke, EmbolicUnited States
-
Mahidol UniversityNot yet recruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke SurvivorsThailand
-
Mahidol UniversityRecruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke PatientThailand
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
Fondazione Don Carlo Gnocchi OnlusScuola Superiore Sant'Anna di Pisa; Fondazione Policlinico Universitario Campus...Not yet recruitingStroke | Stroke Hemorrhagic | Upper Limb Rehabilitation | Stroke IschemicItaly
-
Samsung Medical CenterCompletedChronic Stroke | Subacute Stroke | ExoskeletonSouth Korea
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
Clinical Trials on Motor rehabilitation
-
Istituti Clinici Scientifici Maugeri SpARecruitingCognitive Impairment | Dementia | Vascular Dementia | Dementia, Mixed | Comorbidities and Coexisting ConditionsItaly
-
Universita di VeronaRecruitingMuscular Dystrophies | Rehabilitation | Fear of Falling | Duchenne Muscular Dystrophy (DMD)Italy
-
Azienda Unita' Sanitaria Locale Di ModenaAzienda Unita Sanitaria Locale Reggio Emilia; University of Modena and Reggio... and other collaboratorsCompletedAmyotrophic Lateral SclerosisItaly
-
I.R.C.C.S. Fondazione Santa LuciaCompleted
-
Universitat Pompeu FabraHospital del Mar; Hospital Vall d'HebronCompletedStroke | Hemiparesis | Movement Disorder | Functional Independence
-
IRCCS San Camillo, Venezia, ItalyRecruitingMotor Disorders | Neurological DiseaseItaly
-
Samsung Medical CenterCompletedStroke | Rehabilitation | Motor FunctionKorea, Republic of
-
University Hospital, MontpellierCompleted
-
University of PadovaProf. S Masiero, University of Padova, Italy; Dr. A. Venturin, General Hosipital... and other collaboratorsCompletedCritical Illness | COVID | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Corona Virus Disease 19 (COVID-19)Italy
-
National Central University, TaiwanCompleted